Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00324966 | Liver | Cirrhotic | response to lipopolysaccharide | 111/4634 | 343/18723 | 8.15e-04 | 5.95e-03 | 111 |
GO:00603372 | Liver | Cirrhotic | type I interferon signaling pathway | 23/4634 | 50/18723 | 8.62e-04 | 6.22e-03 | 23 |
GO:00092666 | Liver | Cirrhotic | response to temperature stimulus | 63/4634 | 178/18723 | 9.38e-04 | 6.66e-03 | 63 |
GO:003109812 | Liver | Cirrhotic | stress-activated protein kinase signaling cascade | 83/4634 | 247/18723 | 1.04e-03 | 7.28e-03 | 83 |
GO:00705553 | Liver | Cirrhotic | response to interleukin-1 | 52/4634 | 143/18723 | 1.27e-03 | 8.54e-03 | 52 |
GO:005140312 | Liver | Cirrhotic | stress-activated MAPK cascade | 80/4634 | 239/18723 | 1.43e-03 | 9.54e-03 | 80 |
GO:00022376 | Liver | Cirrhotic | response to molecule of bacterial origin | 113/4634 | 363/18723 | 3.23e-03 | 1.81e-02 | 113 |
GO:0071347 | Liver | Cirrhotic | cellular response to interleukin-1 | 41/4634 | 113/18723 | 4.08e-03 | 2.19e-02 | 41 |
GO:007190011 | Liver | Cirrhotic | regulation of protein serine/threonine kinase activity | 110/4634 | 359/18723 | 6.19e-03 | 3.08e-02 | 110 |
GO:004586011 | Liver | Cirrhotic | positive regulation of protein kinase activity | 117/4634 | 386/18723 | 7.07e-03 | 3.41e-02 | 117 |
GO:003460512 | Liver | HCC | cellular response to heat | 53/7958 | 69/18723 | 6.62e-09 | 1.70e-07 | 53 |
GO:000940811 | Liver | HCC | response to heat | 76/7958 | 110/18723 | 1.48e-08 | 3.58e-07 | 76 |
GO:00022211 | Liver | HCC | pattern recognition receptor signaling pathway | 107/7958 | 172/18723 | 1.37e-07 | 2.58e-06 | 107 |
GO:003434011 | Liver | HCC | response to type I interferon | 43/7958 | 58/18723 | 9.93e-07 | 1.50e-05 | 43 |
GO:000166612 | Liver | HCC | response to hypoxia | 172/7958 | 307/18723 | 1.06e-06 | 1.59e-05 | 172 |
GO:003629312 | Liver | HCC | response to decreased oxygen levels | 179/7958 | 322/18723 | 1.29e-06 | 1.87e-05 | 179 |
GO:007048212 | Liver | HCC | response to oxygen levels | 191/7958 | 347/18723 | 1.42e-06 | 2.03e-05 | 191 |
GO:000756822 | Liver | HCC | aging | 185/7958 | 339/18723 | 4.28e-06 | 5.50e-05 | 185 |
GO:006033711 | Liver | HCC | type I interferon signaling pathway | 37/7958 | 50/18723 | 6.13e-06 | 7.52e-05 | 37 |
GO:000724912 | Liver | HCC | I-kappaB kinase/NF-kappaB signaling | 156/7958 | 281/18723 | 6.66e-06 | 8.00e-05 | 156 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05171 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
hsa05132 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa05130 | Colorectum | AD | Pathogenic Escherichia coli infection | 79/2092 | 197/8465 | 1.05e-06 | 1.36e-05 | 8.65e-06 | 79 |
hsa05135 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa04722 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa05417 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
hsa05170 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa051711 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
hsa051321 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa051301 | Colorectum | AD | Pathogenic Escherichia coli infection | 79/2092 | 197/8465 | 1.05e-06 | 1.36e-05 | 8.65e-06 | 79 |
hsa051351 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa047221 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa054171 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
hsa051701 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa051712 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
hsa051322 | Colorectum | SER | Salmonella infection | 77/1580 | 249/8465 | 1.56e-06 | 2.35e-05 | 1.71e-05 | 77 |
hsa051302 | Colorectum | SER | Pathogenic Escherichia coli infection | 60/1580 | 197/8465 | 3.63e-05 | 4.31e-04 | 3.13e-04 | 60 |
hsa051352 | Colorectum | SER | Yersinia infection | 43/1580 | 137/8465 | 2.15e-04 | 2.10e-03 | 1.52e-03 | 43 |
hsa051702 | Colorectum | SER | Human immunodeficiency virus 1 infection | 58/1580 | 212/8465 | 1.08e-03 | 8.56e-03 | 6.21e-03 | 58 |
hsa047222 | Colorectum | SER | Neurotrophin signaling pathway | 35/1580 | 119/8465 | 2.80e-03 | 2.02e-02 | 1.47e-02 | 35 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IRAK1 | SNV | Missense_Mutation | | c.1748A>G | p.Asn583Ser | p.N583S | P51617 | protein_coding | tolerated(0.07) | probably_damaging(0.996) | TCGA-A8-A079-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
IRAK1 | SNV | Missense_Mutation | | c.1263N>C | p.Gln421His | p.Q421H | P51617 | protein_coding | deleterious(0.02) | probably_damaging(0.925) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
IRAK1 | SNV | Missense_Mutation | rs782334259 | c.1984N>G | p.Ile662Val | p.I662V | P51617 | protein_coding | tolerated(0.1) | probably_damaging(0.984) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
IRAK1 | insertion | In_Frame_Ins | novel | c.464_465insCCCCTCTGTGAGATTTCCCGGGGC | p.Pro156_Glu157insSerValArgPheProGlyAlaPro | p.P156_E157insSVRFPGAP | P51617 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IRAK1 | SNV | Missense_Mutation | novel | c.335N>A | p.Gly112Asp | p.G112D | P51617 | protein_coding | tolerated(0.16) | benign(0.006) | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
IRAK1 | SNV | Missense_Mutation | novel | c.1555N>C | p.Glu519Gln | p.E519Q | P51617 | protein_coding | tolerated(0.15) | probably_damaging(0.998) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
IRAK1 | insertion | Nonsense_Mutation | novel | c.333_334insTAAA | p.Gly112Ter | p.G112* | P51617 | protein_coding | | | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
IRAK1 | SNV | Missense_Mutation | novel | c.505N>G | p.Pro169Ala | p.P169A | P51617 | protein_coding | deleterious(0.01) | benign(0.165) | TCGA-A6-2683-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | irinotecan | PD |
IRAK1 | SNV | Missense_Mutation | | c.1936N>A | p.Ala646Thr | p.A646T | P51617 | protein_coding | tolerated(0.6) | benign(0.015) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
IRAK1 | SNV | Missense_Mutation | | c.1141A>T | p.Thr381Ser | p.T381S | P51617 | protein_coding | deleterious(0.01) | possibly_damaging(0.874) | TCGA-CK-4947-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Other, specify in notes | folinic | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | | PF-562271 | PF-00562271 | |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 249565765 | | |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | | GEFITINIB | GEFITINIB | |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | | GW441756X | GW441756X | |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | | LINIFANIB | LINIFANIB | |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 249565764 | | |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 385612233 | | |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | | TAMATINIB | R-406 | |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | | RG-1530 | RG-1530 | |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 348353615 | | |